Hover over a term you want explained. If you need more details, then click on the term and a new tab will open with a full details page.
ANKTIVA (N-803) Plus BCG is a combined treatment used for a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). This cancer is found only in the inner lining of the bladder and has not spread into the muscle layer. BCG (Bacillus Calmette-Guérin) is a standard treatment that uses a weakened form of bacteria to stimulate the immune system to attack cancer cells in the bladder. However, some patients’ cancers do not respond or stop responding to BCG alone, which is called BCG-unresponsive NMIBC. For these patients, ANKTIVA (N-803) is added to BCG. N-803 is an immune system booster known as an IL-15 superagonist, which helps activate immune cells more strongly. The combination is given directly into the bladder once a week for six weeks to help the body better fight the cancer.
When bladder cancer does not respond to BCG alone, treatment options have traditionally been limited and often involved surgery to remove the bladder (cystectomy). ANKTIVA (N-803) Plus BCG offers a newer option that can help many patients clear their cancer and avoid surgery. Clinical studies have shown promising results, with many patients experiencing complete cancer clearance and lasting effects for months or years. Most patients tolerate this treatment well, with side effects usually mild to moderate, such as bladder irritation or discomfort. It is an important option for patients and doctors seeking to manage BCG-unresponsive NMIBC with less invasive methods.
If you or a loved one is facing bladder cancer that has not responded to BCG, you might hear about ANKTIVA (N-803) Plus BCG during discussions about treatment options. Your care team may explain that this treatment is given directly into the bladder through a catheter, typically once a week for six weeks. It aims to boost the immune system’s ability to fight cancer cells more effectively than BCG alone. You may see this term in your treatment plan, clinical notes, or educational materials. Side effects are usually mild and may include bladder irritation or discomfort.
ANKTIVA (N-803) Plus BCG may appear in your medical records, treatment plans, or discussions about clinical trials. It might also be mentioned in drug information sheets or educational materials provided by your healthcare team. Sometimes it is referred to by other names such as N-803 or nogapendekin alfa inbakicept, so comparing terms can help avoid confusion.
Hearing about ANKTIVA (N-803) Plus BCG does not mean the cancer is cured or that surgery will definitely be avoided. It is an option to try when BCG alone has not worked, but it does not guarantee success. It is also not an experimental or unproven treatment—it has been approved by the U.S. Food and Drug Administration (FDA) for certain patients—but it may not be suitable for everyone. Ongoing monitoring is needed to check how well the treatment is working and to watch for any return or progression of cancer.
This information is educational and cannot decide what is safe or appropriate for any individual patient. If you see this term in your medical records or hear it from your care team, the best next step is to ask your healthcare provider what it means for your specific situation. They can explain how this treatment fits your diagnosis, what to expect, and how it compares to other options. Always discuss any questions or concerns with your oncology team to make informed decisions about your care.